Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?

Klaudia Stempa 1,* 1, Dominika Wokolorczyk 1, Wojciech Kluźniak 1, Emilia Rogoża-Janiszewska 1, Karolina Maliniska 1, Helena Rudnicka 1, Tomasz Huzarski 1,2, Jacek Gronwald 1, Katarzyna Głiniewicz 1, Tadeusz Dębniak 1, Anna Jakubowska 1,2, Marcin Lener 1, Joanna Tomiczek-Szwiec 4, Paweł Domagała 5, Malwina Suszynska 6, Piotr Kozlowski 6, Tomasz Kluz 7, Mariusz Naczk 8, Jan Łubiński 1, Steven A. Narod 9,10, Mohammad R. Akbari 9,10, Cezary Cybulski 1,* 1, and on behalf of the Polish Hereditary Prostate Cancer Consortium.

Abstract: The current cancer testing gene panels tend to be comprehensive rather than site-specific. BARD1 is one of the genes commonly included in the testing panels. Mutations in BARD1 confer an increase in the risk for breast cancer, but it is not studied whether or not they predispose to prostate cancer. To establish whether BARD1 mutations predispose to prostate cancer, we sequenced BARD1 in 390 hereditary prostate cancer cases, genotyped 5715 men with unselected prostate cancer and 10,252 controls for three recurrent rare BARD1 variants in Poland. We did not see an elevated prostate risk cancer given p.Q564X truncating mutation, p.R658C missense mutation and p.R659= synonymous variant. Neither variant influenced prostate cancer susceptibility gene.

Simple Summary: Current cancer testing gene panels tend to be comprehensive. One of the genes commonly included in the testing panels is BARD1. To establish whether BARD1 mutations predispose to prostate cancer, we sequenced BARD1 in 390 hereditary prostate cancer cases, genotyped 5715 men with unselected prostate cancer and 10,252 controls for three recurrent rare BARD1 variants in Poland. We did not see an elevated prostate risk cancer given p.Q564X truncating mutation, p.R658C missense mutation and p.R659= synonymous variant. Neither variant influenced prostate cancer susceptibility gene. Our study is the first to evaluate the association between BARD1 mutations and prostate cancer susceptibility. It is not justified to inform men about increased prostate cancer risk in case of identification of a BARD1 mutation. However, a female relative of a man with a BARD1 mutation may benefit from this information and be tested, because BARD1 is a breast cancer susceptibility gene.
0.57 and 0.93) nor did they influence prostate cancer characteristics or survival. We conclude that men with a BARD1 mutation are not at elevated prostate cancer risk. It is not justified to inform men about increased prostate cancer risk in case of identification of a BARD1 mutation. However, a female relative of a man with a BARD1 mutation may benefit from this information and be tested for the mutation, because BARD1 is a breast cancer susceptibility gene.

**Keywords:** BARD1; mutation; prostate cancer; risk; survival

1. Introduction

Prostate cancer is the most heritable cancer in men (estimated heritability 57%) [1–3]. The high heritability is attributable to the additive effects of multiple low-risk single nucleotide polymorphisms (SNPs) and to rare germline mutations in a number of susceptibility genes [4–10]. Therefore, testing for elevated risk of prostate cancer can be conducted based on SNPs personalized risks scores (PRS) and cancer gene panels.

Recent multiancestry meta-analysis of prostate cancer genome-wide association studies including 107,247 cases and 127,006 controls identified 86 new genetic risk variants independently associated with prostate cancer risk, bringing the total to 269 known risk variants. The top genetic risk score decile was associated with odds ratios that ranged from 5.06 (95% confidence interval (CI) 4.84–5.29) for men of European ancestry to 3.74 (95% CI 3.36–4.17) for men of African ancestry. This study supported the PRS as an important approach for personalized risk prediction [11].

Several prostate cancer susceptibility genes have been identified to date, including those associated with high risk of prostate cancer (BRCA2 and HOXB13-up to eight-fold overall risk), moderate risk (BRCA1-up to 3.8-fold; DNA mismatch repair genes MLH1, MSH2, MSH6, PMS2 and EPCAM up to 2.3 fold increased for all males from Lynch syndrome families), and the genes with limited data regarding risk estimates including CHEK2, ATM and NBN. There are also genes which were associated only with aggressive disease (i.e., PALB2) or genes which mutations were detected only in metastatic prostate cancer (i.e., RAD51C-D, BRIPI, Fanconi anemia genes). It should be considered that the spectrum of mutations in prostate cancer susceptibility genes may be different in diverse populations. There are race-associated germline mutations/variants, i.e., RET and SMAD4 mutations may be unique to African-American men [12]. Germline mutation testing becomes important for prostate cancer treatment, management and hereditary cancer assessment. Testing panels include genes with strong, limited, and unknown risk for prostate cancer and also genes conferring risks for other cancer types. Recently, recommendations for panel choice and priority genes to test in men with prostate cancer and men at high risk for prostate cancer were developed [12]. However, the current multigene genetic testing options include focused, guideline-based, comprehensive, and reflex panels, and it is challenging to make a clear decision which panel to choose depending on particular clinical situation (i.e., for men with metastatic disease, nonmetastatic disease, men at increased prostate cancer risk) to balance the benefits and limitations of expanded testing [12]. In particular, this issue applies to comprehensive panels which analyze many genes associated with multisite cancer susceptibility. For example, The Invitae Common Hereditary Cancers panel tests for mutations in forty-seven genes, which are associated with, e.g., hereditary prostate cancer, hereditary breast and/or ovarian cancer, and Lynch syndrome.

One of the genes commonly included in the testing panels is BARD1 (BRCA1 associated RING domain 1 gene). Mutations in the BARD1 gene confer a two- to three-fold elevated breast cancer risk, but it has not been determined whether or not they predispose to prostate cancer [13]. This is important for male members of families where a testing panel has revealed a BARD1 mutation and for genetic counselors who consider offering testing to male family members. In the event that a BARD1 mutation is found, the men will wish to know if they face an elevated risk for prostate cancer.
BARD1 acts in the BRCA1 gene dependent pathway by forming heterodimers with BRCA1. The interaction between the two proteins is essential for maintaining the stabilization of the BRCA1 protein as well as for the newly formed BRCA1-BARD1 complex. [14]. This complex has activity of E3 ubiquitin ligase, is involved in DNA damage repair, cell cycle control, regulation of hormone signaling, and apoptosis [15]. Because BRCA1 is a prostate cancer susceptibility gene (with an estimated risk for prostate cancer of two- to four-fold by the age of 65) [16–19], and the BRCA1 protein interacts with the BARD1 protein, we considered BARD1 to be a candidate prostate cancer susceptibility gene. We sequenced the BARD1 gene in 390 Polish men with hereditary prostate cancer. Then, we genotyped 5715 patients with unselected prostate cancer, and 10,252 cancer-free controls for three recurrent variants of BARD1 in the Polish population including one truncating variant (c.1690C>T; p.Q564X), one missense mutation (c.1972C>T; p.R658C), and one synonymous substitution (c.1977A>G; p.R659=).

2. Results

First, we fully sequenced the BARD1 gene in 390 Polish patients from families with hereditary prostate cancer. No truncating mutations were identified.

Then, we genotyped 5715 patients with prostate cancer and 10,252 cancer-free controls for three rare changes in BARD1, (i) one definitive truncating mutation (c.1690C>T; p.Q564X) with proved effect on breast cancer risk, and two variants of unknown significance (ii) a missense substitution (c.1972C>T; p.R658C) and (iii) one synonymous substitution (c.1977A>G; p.R659=). A truncating BARD1 mutation p.Q564X was detected in 7 (0.12%) men with prostate cancer compared to 15 (0.15%) cancer-free individuals (OR = 0.84, p = 0.87). This mutation was not detected in any of the 711 familial prostate cancer cases (from the 5715 unselected prostate cancer cases) (p = 0.62) (Table 1). Then, we analyzed clinical characteristics of patients with prostate cancer who carried BARD1 p.Q564X truncating mutation to those in non-carriers. We saw no difference in the age of diagnosis in mutation carriers compared to non-carriers (mean age of onset was 68.9 versus 67.3, respectively; p = 0.61). Additionally, PSA at the time of diagnosis, Gleason score and tumor stage were similar in patients with the p.Q564X variant compared to non-carriers (Table 2).

Neither of the other two variants of the BARD1 gene, a missense substitution p.R658C and a synonymous change p.R659=, were associated with elevated prostate cancer risk.

A missense variant p.R658C of BARD1 was detected in 39 (0.68%) unselected prostate cancer cases compared to 61 (0.60%) cancer-free controls (OR = 1.15, p = 0.57). The variant was present in 3 (0.42%) of 711 men with familial prostate cancer (from unselected cancers) (OR = 0.71, p = 0.74) (Table 1).

We saw no difference in the age of diagnosis in p.R658C variant carriers compared to non-carriers (mean age of onset was 68.1 versus 67.3, respectively; p = 0.52). In addition, PSA at the time of diagnosis, Gleason score and tumor stage were similar in patients with the p.R658C missense mutation compared to non-carriers (Table 2).

A synonymous variant p.R659= of BARD1 was detected in 19 (0.33%) men with unselected prostate cancer and in 35 (0.34%) cancer-free controls (OR = 0.97, p = 0.93). It was identified in 0.56% of 711 familial prostate cancer cases, but the difference was marginal (OR = 1.65), and not statistically significant (p = 0.53) (Table 1). The characteristics of patients affected by prostate cancer with and without the p.R659= variant was similar. The mean age of onset in patients with BARD1 p.R659= variant versus that seen in non-carriers was similar (64.6 versus 67.3, respectively; p = 0.18). The PSA level at the time of diagnosis, Gleason score and tumor stage were also similar in men with the p.R659= variant compared to non-carriers.
Table 1. Prevalence of BARD1 variants in 5715 patients with prostate cancer and 10,252 cancer-free controls.

| Group                  | Number Total | Number Positive | %     | OR     | 95% CI       | p-Value |
|------------------------|--------------|-----------------|-------|--------|--------------|---------|
| **Unselected Cases**   |              |                 |       |        |              |         |
| c.1690 C>T            | 5715         | 7               | 0.12% | 0.84   | 0.34–2.05   | 0.87    |
| c.1972 C>T            | 5715         | 39              | 0.68% | 1.15   | 0.77–1.72   | 0.57    |
| c.1977 A>G            | 5715         | 19              | 0.33% | 0.97   | 0.56–1.70   | 0.93    |
| **Familial cases**    |              |                 |       |        |              |         |
| c.1690 C>T            | 711          | 0               | 0.00% | 0.46   | 0.03–7.78   | 0.62    |
| c.1972 C>T            | 711          | 3               | 0.42% | 0.71   | 0.22–2.26   | 0.74    |
| c.1977 A>G            | 711          | 4               | 0.56% | 1.65   | 0.59–4.66   | 0.53    |
| **Controls**          |              |                 |       |        |              |         |
| **Males**             |              |                 |       |        |              |         |
| c.1690 C>T            | 5545         | 8               | 0.14% |        |              |         |
| c.1972 C>T            | 5545         | 35              | 0.63% |        |              |         |
| c.1977 A>G            | 5545         | 21              | 0.38% |        |              |         |
| **Females**           |              |                 |       |        |              |         |
| c.1690 C>T            | 4707         | 7               | 0.15% |        |              |         |
| c.1972 C>T            | 4707         | 26              | 0.55% |        |              |         |
| c.1977 A>G            | 4707         | 14              | 0.30% |        |              |         |
| **All controls**      |              |                 |       |        |              |         |
| c.1690 C>T            | 15           | 10,252          | 0.15% | Ref.   | -            | -       |
| c.1972 C>T            | 61           | 10,252          | 0.60% | Ref.   | -            | -       |
| c.1977 A>G            | 35           | 10,252          | 0.34% | Ref.   | -            | -       |

Familial cases (n = 711) are derived from a series of unselected cases.

Table 2. Characteristics of patients with prostate cancer who carry a BARD1 variant (7 patients with c.1690C>T, 39 patients with c.1972C>T and 19 men with c.1977A>G) compared to BARD1 variant-negative prostate cancer cases (5650 non-carriers).

| Category                  | c.1690 C>T Positive Cases (n = 7) | p-Value | c.1972 C>T Positive Cases (n = 39) | p-Value | c.1977 A>G Positive Cases (n = 19) | p-Value | BARD1 Variant Negative Cases (n = 5650) |
|---------------------------|-----------------------------------|---------|-----------------------------------|---------|-----------------------------------|---------|----------------------------------------|
| **Age of diagnosis**      | mean (range)                      |         | mean (range)                      |         | mean (range)                      |         |                                        |
|                           | Age of diagnosis                  |         |                                   |         |                                   |         |                                        |
|                           | mean (range)                      |         |                                   |         |                                   |         |                                        |
|                           | 68.9 (64–77)                      | 0.61    | 68.1 (51–93)                      | 0.52    | 64.6 (47–77)                      | 0.18    | 67.3 (35–93)                           |
|                           | 0.0% (0/7)                        |         | 12.8% (3/29)                      |         | 15.8% (3/19)                      |         | 18.5% (1047/5650)                      |
|                           | 61.4% (5/7)                       | 0.29    | 51.3% (20/39)                     | 0.48    | 68.4% (13/19)                     | 0.06    | 44.4% (2510/5650)                      |
|                           | 28.6% (2/7)                       | 0.94    | 35.9% (14/39)                     | 0.88    | 15.8% (3/19)                      | 0.09    | 37.0% (2093/5650)                      |
|                           |                                   |         |                                   |         |                                   |         |                                        |
| **PSA at diagnosis**      | median (range)                    |         |                                   |         |                                   |         |                                        |
|                           | 12.0 (3.1–443.3)                  | 0.66    | 11.0 (0.24–104.0)                 | 0.22    | 10.7 (0.33–42.0)                  | 0.93    | 10.7 (0.1–5000)                        |
|                           | 14.3% (1/7)                       | 0.89    | 2.7% (1/37)                       | 0.64    | 11.1% (2/18)                      | 0.66    | 5.9% (153/2614)                        |
|                           | 28.6% (2/7)                       | 0.75    | 37.8% (14/37)                     | 0.76    | 38.9% (7/18)                      | 0.81    | 41.6% (1089/2614)                      |
|                           | 28.6% (2/7)                       | 0.81    | 24.3% (9/37)                      | 0.96    | 27.8% (5/18)                      | 0.97    | 24.6% (644/2614)                       |
|                           | 28.6% (2/7)                       | 0.97    | 35.1% (13/37)                     | 0.43    | 22.2% (4/18)                      | 0.79    | 27.9% (728/2614)                       |
Neither of the other two variants of the BARD1 gene, a missense substitution p.R658C and a synonymous change p.R659=, were associated with elevated prostate cancer risk. A missense variant p.R658C of BARD1 was detected in 39 (0.68%) unselected prostate cancer cases compared to 61 (0.60%) cancer-free controls (OR = 1.15, \( p = 0.57 \)). The variant was present in 3 (0.42%) of 711 men with familial prostate cancer (from unselected cancers) (OR = 0.71, \( p = 0.74 \)) (Table 1).

We saw no difference in the age of diagnosis in p.R658C variant carriers compared to non-carriers (mean age of onset was 68.1 versus 67.3, respectively; \( p = 0.50 \)). In addition, PSA at the time of diagnosis, Gleason score and tumor stage were similar in patients with the p.R658C missense mutation compared to non-carriers (Table 2).

A synonymous variant p.R659= of BARD1 was detected in 19 (0.33%) men with unselected prostate cancer and in 35 (0.34%) cancer-free controls (OR = 0.97, \( p = 0.93 \)). It was identified in 0.56% of 711 familial prostate cancer cases, but the difference was marginal (OR = 1.65), and not statistically significant (\( p = 0.53 \)) (Table 1). The characteristics of patients affected by prostate cancer with and without the p.R659= variant was similar. The mean age of onset in patients with BARD1 p.R659= variant versus that seen in non-carriers was similar (64.6 versus 67.3, respectively; \( p = 0.18 \)). The PSA level at the time of diagnosis, Gleason score and tumor stage were also similar in men with the p.R659= variant compared to non-carriers.

During the follow up time of 102 months, there were 3 deaths recorded in the 7 BARD1 p. Q564X mutation carriers (42.9%; \( p = 0.98 \)), 17 deaths in 39 (43.6%, \( p = 0.88 \)) missense

### Table 2. Cont.

| Category | c.1690 C>T Positive Cases \((n = 7)\) | \( p \)-Value | c.1972 C>T Positive Cases \((n = 39)\) | \( p \)-Value | c.1977 A>G Positive Cases \((n = 19)\) | \( p \)-Value | BARD1 Variant Negative Cases \((n = 5650)\) |
|----------|----------------------------------------|-------------|----------------------------------------|-------------|----------------------------------------|-------------|----------------------------------------|
| **Gleason score** | | | | | | | |
| \(<7\) | 42.9% \((3/7)\) | 0.82 | 50.0% \((18/36)\) | 0.72 | 41.2% \((7/17)\) | 0.40 | 54.4% \((1647/3028)\) |
| \(7\) | 28.6% \((2/7)\) | 0.65 | 27.8% \((10/36)\) | 0.48 | 41.2% \((7/17)\) | 0.09 | 27.4% \((830/3028)\) |
| \(>7\) | 28.6% \((2/7)\) | 0.82 | 22.2% \((8/36)\) | 0.68 | 17.6% \((3/17)\) | 0.95 | 18.2% \((551/3028)\) |
| **Stage** | | | | | | | |
| T1/2 | 71.4% \((5/7)\) | 0.80 | 78.8% \((26/33)\) | 0.83 | 80.0% \((12/15)\) | 0.92 | 75.6% \((1726/2283)\) |
| T3/4 | 28.6% \((2/7)\) | 0.79 | 21.2% \((7/33)\) | 0.83 | 20.0% \((3/15)\) | 0.92 | 24.4% \((557/2283)\) |
| **Positive family history** | | | | | | | |
| positive | 0.0% \((0/7)\) | 0.55 | 10.0% \((3/30)\) | 0.59 | 23.5% \((4/17)\) | 0.54 | 15.2% \((704/4633)\) |

*—Reference group for \( p \)-value calculations.

![Figure 1](image-url)  
**Figure 1.** Survival curves of men with prostate cancer and a BARD1 variant (7 patients with c.1690C>T, 39 patients with c.1972C>T and 19 men with c.1977A>G) and of BARD1 variant negative prostate cancer patients (5650 non-carriers). Footnote to Figure 1: BARD1 variant negative prostate cancer patients – prostate cancer patients negative for c.1690 C>T, c.1972 C>T and c.1977 A>G variants of BARD1.

During the follow up time of 102 months, there were 3 deaths recorded in the 7 BARD1 p. Q564X mutation carriers (42.9%; \( p = 0.98 \)), 17 deaths in 39 (43.6%, \( p = 0.88 \)) missense
variant p.R658C carriers, 7 deaths in 19 (36.8%, \( p = 0.79 \)) p.R659= variant carriers, compared to 2397 deaths among the 5650 non-carriers (42.4%), but neither difference was significant. Kaplan–Maier curves for patients with each of 3 BARD1 variants and for non-carriers are presented in Figure 1.

We did not see a statistical difference in 5-year survival for carriers of three BARD1 variants-p.Q564X, p.R658C and p.R659= (survival 71%, 83% and 73%, respectively) compared to non-carriers (72%), all differences were not significant (\( p \)-values between 0.11 and 0.97). Additionally, 10-year survival for carriers of the three BARD1 variants (survival 57%, 55% and 49%, respectively) was similar to that seen in non-carriers (54%), (all \( p \)-values between 0.82 and 0.98). The unadjusted and adjusted for age hazard ratios (HRs) for death associated with each of the three BARD1 variants are provided in Table 3. Crude HRs for the p.Q564X, p.R658C and p.R659= variants were 0.95, 0.94 and 0.92, respectively, and neither was significant.

Table 3. Survival of prostate cancer patients with a BARD1 variant (7 patients with c.1690C>T, 39 patients with c.1972C>T and 19 men with c.1977A>G) and of BARD1 variant-negative prostate cancer patients (5650 non-carriers).

| Category                        | Patients with c.1690 C>T Truncating Mutation (7 Cases) | Patients with c.1972 C>T Missense Variant (39 Cases) | Patients with c.1977 A>G Synonymous Variant (19 Cases) | BARD1 * Variant Negative Patients (5650 Cases) |
|---------------------------------|--------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|--------------------------------------------------|
| Proportion of deceased          | 42.9% (3/7)                                            | 43.6% (17/39)                                         | 36.8% (7/19)                                          | 42.4% (2397/5650)                                 |
| Median survival                 | nd                                                     | 111                                                   | nd                                                    | 140                                              |
| 5-year survival                 | 71%                                                   | 83%                                                   | 73%                                                   | 72%                                              |
| 10-year survival                | 57%                                                   | 55%                                                   | 49%                                                   | 54%                                              |
| Crude HR                        | 0.95                                                  | 0.94                                                  | 0.92                                                  |                                                  |
| 95%CI                           | 0.31–2.92                                             | 0.59–1.51                                             | 0.44–1.92                                             | ref.                                             |
| \( p \)-value                   | 0.93                                                  | 0.81                                                  | 0.82                                                  |                                                  |
| Age adjusted                    |                                                        |                                                       |                                                       |                                                  |
| HR                              | 0.96                                                  | 0.87                                                  | 1.06                                                  |                                                  |
| 95% CI                          | 0.21–2.96                                             | 0.54–1.40                                             | 0.51–2.22                                             | ref.                                             |
| \( p \)-value                   | 0.94                                                  | 0.56                                                  | 0.87                                                  |                                                  |

*—Reference group for OR and \( p \)-value calculations.

We were able to analyze tumor DNA of three men with BARD1 truncating mutation p.Q564X, three patients with a missense variant p.R658C, and three men with a synonymous change p.R659= for LOH at the BARD1 locus. Sanger sequencing did not show LOH in any tumor of 9 analyzed patients (Figure 2).
3. Discussion

The **BARD1** gene is located on chromosome 2 (locus 2q34-35). It consists of 11 exons. The gene encodes a 777-amino acid protein. The BARD1 protein contains N-terminal RING domain with a zinc finger motif, three ankyrin repeat domains (ANK) in the central part of the protein, and two BRCT domains at the C-terminal end. The BARD1 and BRCA1 proteins form a heterodimer complex. The interaction between the two proteins is essential for maintaining the stabilization of BRCA1 [14,19–21]. The BRCA1/BARD1 heterodimer acts in the DNA damage response signaling pathway, cell cycle control, hormone signaling modulation and chromatin structural maintenance [22,23]. For example, BRCA1 and BARD1 bind DNA and interact with RAD51, BRCA1–BARD1 complex enhances the recombinase activity of RAD51, and have a role in homologous recombination repair [24]. BARD1 also plays a role in the maintenance of genome integrity by interacting with other proteins including p53 [25,26].

To date, little is known about cancer susceptibility in carriers of **BARD1** mutations. The most commonly studied is the association between **BARD1** and breast cancer [19,20,27]. Most recent, large association analysis of approximately 110,000 women performed by Breast Cancer Association Consortium provided evidence of an association between truncating **BARD1** mutation and an elevated risk of breast cancer [13]. In that study, the authors identified 62 carriers of truncating **BARD1** mutations in 58,728 women with breast cancer compared to 32 carriers in 52,976 controls (OR = 2.09; 95% CI, 1.35 to 3.23; p = 0.0001). Common variants in **BARD1** have also been related to a genetic susceptibility to neuroblastomas, colorectal and lung cancer but based on single reports [28–30]. Therefore, the evidence of the association of **BARD1** mutations with a genetic predisposition to cancers other than breast cancer is controversial. There are no studies to date which reported the influence of **BARD1** mutations on prostate cancer risk.

We selected three Polish **BARD1** rare recurrent variants for large case–control study: a founder deleterious mutation p.Q564X, localized in exon 8 of the **BARD1** gene, and two single base substitutions of unknown function, a missense mutation p.R658C and a **Figure 2.** LOH analysis in tumors from nine patients with **BARD1** variants (c.1690 C>T, c.1972 C>T and c.1977 A>G). LOH was not observed in any of the nine studied prostate cancers. Localization of **BARD1** variants is marked with an arrow (↓).

[Image: LOH analysis in tumors from nine patients with BARD1 variants (c.1690 C>T, c.1972 C>T and c.1977 A>G). LOH was not observed in any of the nine studied prostate cancers. Localization of BARD1 variants is marked with an arrow (↓).]
synonymous change p.R659=, both located in exon 10 of BARD1, previously detected in our population [20]. ClinVar defines the p.Q564X mutation as clearly pathogenic. There are conflicting predictions regarding the clinical significance of BARD1 p.R658C and p.R659R changes. ClinVar reports these two variants (p.R658C, p.R659=) as of unknown significance, likely benign or even benign. However, both variants are localized in an important domain of the gene (BRCT domain), and some studies refer to p.R658C and p.R659= as potentially pathological [31–33], so we choose to analyze prostate cancer risk given these two variants as well.

In the current study, we did not observe an increased risk for prostate cancer given any of the three BARD1 variants studied. We also showed that these variants (including a truncating BARD1 mutation) did not influence prostate cancer characteristics or survival among the carriers. Finally, we did not observe LOH at the BARD1 locus in prostate cancers. In aggregate, our study suggests that BARD1 mutations do not predispose to prostate cancer.

Most interestingly, we found no association of the Polish founder BARD1 deleterious mutation (p.Q564X) with elevated risk for prostate cancer (OR = 0.84, 95%CI 0.34–2.05). Previously, we reported that the p.Q564X mutation conferred a two-fold increased risk of breast cancer (p = 0.04) [20]. In the current study, we also analyzed the frequency of BARD1 variants in prostate cancer patients with relatives with breast cancer. There were 407 men with prostate cancer and a positive history of breast cancer in first or second degree relatives. Among these men, the p.Q564X mutation frequency was significantly higher than that seen in 10,252 cancer-free controls (0.74% vs. 0.15%; OR = 5.07, p = 0.026). In contrast, the p.R658C missense variant frequency was similar in prostate cancer patients with a family history of breast cancer and in cancer-free controls (0.49% vs. 0.60%; OR = 0.83, p = 0.79). The prevalence of the p.R659= variant was 0% in prostate cancer patients with a family history of breast cancer compared to 0.34% in cancer-free controls (OR = 0.35, p = 0.46). These results suggest that the p.Q564X deleterious mutation (but not p.R658C and p.R659= variants) predisposes to breast cancer, however this truncating mutation does not increase prostate cancer risk.

Our results that BARD1 mutations do not confer increased risk of prostate cancer are in line with several previous reports. No mutations were detected in BARD1 by Invitae by sequencing in 140 African-American patients with prostate cancer and 1695 Caucasian American men with prostate cancer [34]. In a study from the UK of 1281 early-onset cases and 1160 selected controls, no pathogenic for prostate cancer BARD1 mutations were reported [35]. In a large study of 5545 European-ancestry men with prostate cancer, only nine (0.16%) patients carried a BARD1 mutation (six different BARD1 mutations) [36]. No BARD1 mutations were detected in 692 men with metastatic prostate cancer unscreened for age and family history of cancer [37]. In another study of 704 men with metastatic prostate cancer, only one BARD1 mutation was detected (0.14%) compared to 0.09% in 54,802 reference controls from Genome Aggregation database (p = 0.46) [38].

The Polish population is genetically homogenous because it is populated by ethnic Poles. BARD1 p.Q564X founder truncating mutation is seen in 0.15% of the general population of Poland. The presence of this deleterious founder allele enabled us to analyze its association with the risk of prostate cancer in a population based study at reasonable costs. In other populations, founder mutations in BARD1 were not detected and truncating mutations of this gene are very uncommon, identified with an aggregate frequency of about 0.05% or less (different rare truncating mutations combined) [13,19]. Therefore, analysis of the association between BARD1 truncating mutations and prostate cancer risk in other populations would require sequencing of the entire gene in large case–control study (given the ≤0.05% mutation frequency in other ethnic groups, at least approximately 15,000 cases and 30,000 controls should be screened, to have comparable power to our current study).

The limitations of our study include the low number of mutation carriers, so the results of the association of BARD1 variants with clinical characteristics and survival should be interpreted with caution. Additionally, our control group was suboptimal. The aim of the
control group was to estimate the frequency of BARD1 variants in the underlying Polish population. We used both males and females to maximize the number of controls, because the studied variants are rare in the population. Our cases were older than controls, and our controls included both cancer-free men and women. However, both cases and controls were ethnic Poles, and the variants frequency (for each BARD1 variant) was not dependent on age or sex. Therefore, we believe that our population controls are good approximation of age- and sex-matched cancer-free control group.

4. Materials and Methods

4.1. Patients

We studied two non-overlapping series of men with prostate cancer: 390 men with familial prostate cancer and 5715 men with unselected prostate cancer. The first series of cases was derived from a registry of familial cases housed at the Hereditary Cancer Center in Szczecin in Poland. We selected families with strong aggregations of prostate cancer, and those with youngest age of onset in probands and their relatives. The mean number of prostate cancers per family was 2.8. The mean age of diagnosis among the 390 men was 61.6 years (range 38–82). The series is described in detail previously [39].

The second series of cases included 5715 men with prostate cancer who were diagnosed between 1999 and 2015 in 14 centers situated throughout Poland. This study was initiated in Szczecin in 1999 and was extended to include Bialystok and Olsztyn in 2002 and Opole in 2003. Other centers began recruiting between 2005 and 2008 (Koszalin, Gdansk, Lublin, Lodz, Warszawa, Wroclaw, Poznan, Rzeszow, Bydgoszcz, Zabrze). Men with newly diagnosed treatment-naive prostate cancer were invited to participate. Prostate cancer cases enrolled in the study are unselected for age, clinical characteristics (stage, grade, PSA level at time of diagnosis), family history and treatment. Study subjects were asked to participate at the time of diagnosis. The patient participation rate was 85.4%. Patients who provided a blood sample within 6 months of diagnosis were enrolled. Men who provided blood sample above 6 months from diagnosis (n = 63) were excluded. The mean age of diagnosis was 67.3 years (range 35–96 years). A family history was taken either by the construction of a family tree or the completion of a standardized questionnaire. All first- and second-degree relatives diagnosed with prostate cancer and the ages of diagnosis were recorded. A total of 711 men reported at least one first- or second-degree relative with prostate cancer (familial cases). In addition, information was obtained on PSA level at time of diagnosis, grade (Gleason score) and stage, when possible. The vital status (dead or alive) and the date of death of the cases were requested from the Polish Ministry of the Interior and Administration in June 2016 and were obtained in July 2016. Survival data were obtained for all men with prostate cancer.

4.2. Controls

The control group included 10,252 cancer-free adults from the genetically homogeneous population of Poland. The control group consisted of 5545 cancer-free men (age 19–97 years, mean 59.0 years; 1486 men below age 50 years and 4059 men at age 50 or above) and 4707 cancer-free women (age 18 to 94 years, mean 54.0 years; 1865 women below age of 50 years and 2842 women at age 50 or above) from the International Hereditary Cancer Center (IHCC) cohort (Szczecin, Poland) [40–43]. The aim of the control group was to estimate the frequency of the three BARD1 variants in the Polish population. The variants frequencies in controls were not dependent on age or sex. All cases and controls were ethnic Poles. The study was approved by the Ethics Committee of the Pomeranian Medical University in Szczecin.

4.3. Exome Sequencing

The first series of 390 men with hereditary prostate cancer were tested by exome sequencing as described previously [39]. In brief, The Agilent SureSelect human exome kit (V6) was used for capturing sequence target regions. Paired-end sequencing was performed
on a high throughput sequencing cartridge of Illumina NextSeq 500. The mean depth of coverage was approximately \(100 \times\) (range 62 \(\times\) to 171 \(\times\)). On average, 98.8\% (range 87.6\% to 99.0\%) of the CCDS exons were covered at 20x depth of coverage and higher which used for variant calling. We sought to identify protein truncating variants, variants at the consensus splice site likely to be dysfunctional and known pathogenic missense or intronic mutations in \textit{BARD1} gene based on the literature, ClinVar and Human Genome Mutation Database.

4.4. Genotyping

5715 men with unselected prostate cancer and 10,252 controls were genotyped for the three variants of \textit{BARD1} (c.1690 C>T, p.Q564X; c.1972 C>T, p.R658C; c.1977 A>G, p.R659=). Genomic DNA was isolated from 5 to 10 mL of peripheral blood. \textit{BARD1} variants were genotyped using TaqMan assay (Thermo Fisher Scientific, Waltham, MA) using LightCycler\textsuperscript{®} Real-Time PCR 480 System (Roche Life Science, Indianapolis, IN). Laboratory technicians were blinded to case–control status. The primer and probe sequenced used in TaqMan-PCR assays are published in our previous report describing the association between \textit{BARD1} variants and breast cancer [20]. TaqMan assays for the c.1690 C>T (p.Q564X) mutation were previously validated by an analysis of 18 randomly selected mutation carriers and 20 non-carriers by Sanger sequencing analysis on an ABI Prism 3130 genetic analyzer (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer’s protocol. The c.1972 C>T (p.R658C) and c.1977 A>G (p.R659=) variants were validated by the sequencing of 10 carriers and 10 non-carriers (for each variant). The results of TaqMan-PCR genotyping and direct sequencing validation were fully concordant [20].

4.5. Statistical Analysis

The prevalence of the \textit{BARD1} alleles was estimated in prostate cancer cases and population controls and compared. Odds ratios were generated from two-by-two tables and statistical significance was assessed using the Fisher exact test or the chi-squared test where appropriate. Men with prostate cancer, with and without a \textit{BARD1} variant were compared for age at diagnosis, family history and clinical features of the prostate cancers. Means were compared using t-test, and medians were compared using Mann–Whitney test. To estimate survival, Kaplan–Meier curves were constructed. Men were followed from the date of diagnosis (the date of biopsy) until the date of death or July 2016. The median follow up time was 102 months. The vital status was available for all men with prostate cancer. The crude hazard ratio for death (all-cause mortality), for each of three \textit{BARD1} variants was estimated by means of the Cox proportional hazards model. Then, the data was re-analyzed, adjusting for age of diagnosis while also using the Cox proportional hazards model.

4.6. Loss of Heterozygosity Analysis

Formalin-fixed paraffin-embedded (FFPE) tissue samples were analyzed for nine carriers of \textit{BARD1} variants, three of a truncating mutation c.1690C>T (p.Q564X), three of a missense variant c.1972C>T (p.R658C) and three of a synonymous variant c.1977A>G (p.R659=). FFPE tissue samples were obtained from Centers in Szczecin, Opole and Rzeszów. A pathology review of the samples was conducted by a pathologist associated with the study. Loss of heterozygosity (LOH) analysis at the \textit{BARD1} locus was performed in DNA isolated from micro-dissected tumors from nine patients using the methodology described previously [7] with some modifications: (1) DNA was isolated with QIAamp DNA FFPE Tissue Kit (from QIAGEN); (2) For the c.1690 C>G mutation, LOH was analyzed by Sanger sequencing of 190 bp DNA fragment containing the variant using forward primer 5’ TGTCTTTGTCTAGTCTATGGTTT and reverse primer 5’ GCCCCTGCTATAAGTCAAAG); for the c.1972 C>T and c.1977 A>G variants LOH was analyzed by Sanger sequencing of 166 bp fragment containing both variants using forward primer 5’ GTTGTATTAAAGAAAAATACCAGCTG.
5. Conclusions

This study is the first to evaluate the role of BARD1 in genetic susceptibility to prostate cancer. It is not justified to inform men about increased prostate cancer risk in case of identification of a BARD1 mutation using currently existing comprehensive gene testing panels. However, a female relative of a man with a BARD1 mutation may benefit from this information and she may be tested for this mutation, because BARD1 is a breast cancer susceptibility gene.

Author Contributions: K.S. designed the study, analyzed study data and drafted the manuscript; K.S., D.W., W.K., E.R.-J., K.M., K.G. and J.T.-S., selected and prepared DNA samples for genotyping and performed genotyping; T.H., J.G., T.D., T.K., M.N. and C.C. enrolled patients and controls for the study, and collected phenotypic data for the study; K.S., performed statistical analyses; W.K., H.R., M.L. and A.J., performed NGS sequencing; P.D., selected, prepared, and provided tissue samples and performed LOH analysis; M.S., P.K. and M.R.A., performed bioinformatics analysis of NGS sequencing data and assisted in drafting the manuscript; S.A.N. and J.L., assisted in coordination of the study and in drafting the manuscript; C.C. conceived, designed, and coordinated the study and assisted in drafting the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by National Science Centre, Poland; project number: 2015/19/B/NZ2/02439.

Institutional Review Board Statement: The study was approved by the Ethics Committee of the Pomeranian Medical University in Szczecin (IRB No. KB-0012/246/06/18). Patient clinical data have been obtained in a manner conforming with IRB ethical guidelines.

Informed Consent Statement: Informed consent was obtained from all individual participants included in the study.

Data Availability Statement: The main research data supporting the results of this study are included in Tables 1–3 and Figures 1 and 2. Other data can be made available upon reasonable request from the corresponding author.

Acknowledgments: For their help, we thank the members of the Polish Hereditary Prostate Cancer Consortium, which include: Bartłomiej Masojć, Adam Gołab, Bartłomiej Gliniewicz, Andrzej Sikorski, Marcin Słojelewski, Jerzy Świtała, Tomasz Borkowski, Andrzej Borkowski, Andrzej Antczak, Łukasz Wojnar, Jacek Przybyła, Marek Sosnowski, Bartosz Małkiewicz, Romuald Zdrojowy, Paulina Sikorska-Radek, Józef Małych, Jacek Wilkosz, Waldemar Rożyński, Jacek Kłos, Krzysztof Bar, Andrzej Paradysz, Konrad Jersak, Jerzy Niemirowicz, Piotr Słupski, Piotr Jarzemski, Michał Skrzypczyk, Jakub Dobruch, Michał Soczawa, Miroslaw Kordowski, Marcin Życzkowski, Andrzej Borówik, Joanna Bagińska, Kazimierz Krajka, Małgorzata Stawicka, Olga Haus, Hanna Janiszewska, Agnieszka Stembalska, and Maria Małgorzata Sasiadek.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebolo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. *Int. J. Cancer* 2015, 136, E359–E386. [CrossRef] [PubMed]

2. Carter, B.S.; Beaty, T.H.; Steinberg, G.D.; Childs, B.; Walsh, P.C. Mendelian Inheritance of Familial Prostate Cancer (Segregation Analysis/Genetic Epidemiology/Autosomal Dominant Inheritance). *Proc. Natl. Acad. Sci. USA* 1992, 89, 3367–3371. [CrossRef]

3. Mucci, L.A.; Hjelmborg, J.B.; Harris, J.R.; Czene, K.; Havelick, D.J.; Scheike, T.; Graff, R.E.; Holst, K.; Möller, S.; Unger, R.H.; et al. Familial Risk and Heritability of Cancer Among Twins in Nordic Countries HHS Public Access Author Manuscript. *JAMA* 2017, 315, 68–76. [CrossRef]

4. Schumacher, F.R.; Al Olama, A.A.; Berndt, S.I.; Benlloch, S.; Ahmed, M.; Saunders, E.J.; Dadaei, T.; Lengamornlert, D.; Anokian, E.; Cieza-Borrella, C.; et al. Association Analyses of More than 140,000 Men Identify 63 New Prostate Cancer Susceptibility Loci. *Nat. Genet.* 2018, 50, 928–936. [CrossRef]

5. Ewing, C.M.; Ray, A.M.; Lange, E.M.; Zuhlke, K.A.; Robbins, C.M.; Tembe, W.D.; Wiley, K.E.; Isaacs, S.D.; Johng, D.; Wang, Y.; et al. Germline Mutations in HOXB13 and Prostate-Cancer Risk. *New Engl. J. Med.* 2012, 366, 141. [CrossRef] [PubMed]

6. Dong, X.; Wang, L.; Taniguchi, K.; Wang, X.; Cunningham, J.M.; McDonnell, S.K.; Qian, C.; Marks, A.E.; Slager, S.L.; Peterson, B.J.; et al. Mutations in CHEK2 associated with prostate cancer risk. *Am. J. Human Genet.* 2003, 72, 270–280. [CrossRef]
31. Klonowska, K.; Ratajska, M.; Czubak, K.; Kuzniacka, A.; Brozek, I.; Koczkowska, M.; Sniadecki, M.; Debniaik, J.; Wydra, D.; Balut, M.; et al. Analysis of Large Mutations in BARD1 in Patients with Breast and/or Ovarian Cancer: The Polish Population as an Example. Sci. Rep. 2015, 5, 10424. [CrossRef]

32. Ratajska, M.; Matusiak, M.; Kuzniacka, A.; Wasag, B.; Brozek, I.; Biernat, W.; Koczkowska, M.; Debniaik, J.; Sniadecki, M.; Kozlowski, P.; et al. Cancer Predisposing BARD1 Mutations Affect Exon Skipping and Are Associated with Overexpression of Specific BARD1 Isoforms. Oncol. Rep. 2015, 34, 2609–2617. [CrossRef] [PubMed]

33. Pilyugin, M.; André, P.-A.; Ratajska, M.; Kuzniacka, A.; Limon, J.; Tournier, B.B.; Colas, J.; Laurent, G.; Irminger-Finger, I. Antagonizing Functions of BARD1 and Its Alternatively Spliced Variant BARD1δ in Telomere Stability. Oncotarget 2016, 8, 9339–9353. [CrossRef]

34. Sartor, O.; Yang, S.; Ledet, E.; Moses, M.; Nicolosi, P. Inherited DNA-Repair Gene Mutations in African American Men with Prostate Cancer. Oncotarget 2020, 11, 440–442. [CrossRef] [PubMed]

35. Leongamornlert, D.A.; Saunders, E.J.; Wakerell, S.; Whitmore, I.; Dadaev, T.; Cieza-Borrella, C.; Benaffi, S.; Brook, M.N.; Donovan, J.L.; Hamdy, F.C.; et al. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. Eur. Urol. 2019, 76, 329–337. [CrossRef] [PubMed]

36. Darst, B.F.; Dadaev, T.; Saunders, E.; Sheng, X.; Wan, P.; Pooler, L.; Xia, L.Y.; Chanock, S.; Berndt, S.I.; Gapstur, S.M.; et al. Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer. J. Natl. Cancer Inst. 2021, 113, 616–625. [CrossRef]

37. Pritchard, C.C.; Mateo, J.; Walsh, M.F.; De Sarkar, N.; Abida, W.; Beltran, H.; Garofalo, A.; Gulati, R.; Carreira, S.; Eeles, R.; et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New Engl. J. Med. 2016, 375, 443–453. [CrossRef]

38. Yadav, S.; Hart, S.N.; Hu, C.; Hillman, D.; Lee, K.Y.; Gnanaolivu, R.; Na, J.; Polley, E.C.; Couch, F.J.; Kohli, M. Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome. JCO Precis. Oncol. 2019, 3, PO.19.00067. [CrossRef]

39. Wokołorczyk, D.; Kluźniak, W.; Huzarski, T.; Gronwald, J.; Szymiczek, A.; Rusak, B.; Stempa, K.; Gliniewicz, K.; Kashyap, A.; Morawska, S.; et al. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland. Int. J. Cancer 2020, 147, 2793–2800. [CrossRef]

40. Wokołorczyk, D.; Kluźniak, W.; Stempa, K.; Rusak, B.; Huzarski, T.; Gronwald, J.; Gliniewicz, K.; Kashyap, A.; Morawska, S.; Dębiak, T.; et al. PALB2 Mutations and Prostate Cancer Risk and Survival. Br. J. Cancer 2021, 125, 569–575. [CrossRef]

41. Cybulski, C.; Wokołorczyk, D.; Kluźniak, W.; Jakubowska, A.; Górski, B.; Gronwald, J.; Huzarski, T.; Kashyap, A.; Byrski, T.; Dębiak, T.; et al. An Inherited NBN Mutation Is Associated with Poor Prognosis Prostate Cancer. Br. J. Cancer 2013, 108, 461–468. [CrossRef] [PubMed]

42. Cybulski, C.; Carrot-Zhang, J.; Kluźniak, W.; Rivera, B.; Kashyap, A.; Wokołorczyk, D.; Giroux, S.; Nadaf, J.; Hamel, N.; Zhang, S.; et al. Germline RECQL Mutations Are Associated with Breast Cancer Susceptibility. Nat. Genet. 2015, 47, 643–646. [CrossRef] [PubMed]

43. Kluźniak, W.; Wokołorczyk, D.; Rusak, B.; Huzarski, T.; Kashyap, A.; Stempa, K.; Rudnicka, H.; Jakubowska, A.; Szwiec, M.; Morawska, S.; et al. Inherited Variants in BLM and the Risk and Clinical Characteristics of Breast Cancer. Cancers 2019, 11, 1548. [CrossRef] [PubMed]